Evidence map›Paper›PMID 28295259›Full record

ArticleEuropean journal of immunology2017

Applying the TOR(C)QUE in iNKT cells: A new twist in an old tale.

Mihalis Verykokakis, Barbara L Kee

Open access · bronzeAbstract readComment
In one paragraph

Article in European journal of immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Mihalis VerykokakisBiological Sciences Research Center "Alexander Fleming,", 16672, Vari, Greece.
Barbara L KeeDepartment of Pathology and Committee on Immunology, University of Chicago, Chicago, IL, USA.
Alexander Fleming Biomedical Sciences Research Center · GRUniversity of Chicago · US

Funding

Transcriptional Control of Natural Killer Cell DevelopmentR01AI106352 · NIAID · UNIVERSITY OF CHICAGO · PI KEE, BARBARA L. · 2014 to 2023
$4.6M
Mechanisms of E protein transcription factor-dependent iNKT cell expansion and differentiationR01AI123396 · NIAID · UNIVERSITY OF CHICAGO · PI KEE, BARBARA L. · 2017 to 2021
$2.0M
ETS1 function in mature innate lymphoid cellsR21AI115388 · NIAID · UNIVERSITY OF CHICAGO · PI KEE, BARBARA L. · 2015 to 2016
$430k
Analysis of the role of immune deficiency in E2A-/- T cell lymphomagenesisR21AI119894 · NIAID · UNIVERSITY OF CHICAGO · PI KEE, BARBARA L. · 2015 to 2016
$419k
NIAID NIH HHS R01 AI106352NIAID NIH HHS R01 AI123396NIAID NIH HHS R21 AI115388NIAID NIH HHS R21 AI119894
6 · The paper itself

Abstract

The mammalian Target of Rapamycin (mTOR) protein controls the machinery necessary for T-cell activation, differentiation, and memory formation, as a component of mTOR complex 1 (mTORC1) and mTORC2, which function both downstream and upstream of AKT. Invariant natural killer T (iNKT) cells are a unique T-cell subset that exist in a primed state, capable of rapid activation, and produce large quantities of cytokines. iNKT-cell effector differentiation is dependent on the mTORC1 complex; however, the requirements for mTORC2 in iNKT cells have been controversial. In this issue, Sklarz et al. [Eur. J. Immunol. 2017. 47: 516-526] provide a careful analysis of the requirements for the mTORC2 component Rictor in iNKT cells, providing a new twist in this unfolding tale. The authors demonstrate that Rictor is required for iNKT-cell proliferation and survival during the key stage of intrathymic expansion and that Rictor supports the development of NKT17 cells, an effector subset which depends on the transcription factor RORγt and produces interleukin (IL)-17, in both the thymus and the lung. IL-4-producing NKT2 cells develop in the absence of Rictor but the cytotoxic potential of iNKT cells is Rictor-dependent.

Indexed as

TOR Serine-Threonine KinasesAnimalsCell DifferentiationInterleukin-4MiceMice, KnockoutNatural Killer T-CellsT-Lymphocyte SubsetsInterleukin-4TOR Serine-Threonine KinasesCytotoxicityDevelopmentDifferentiationNatural killer T cellNKT17Thymus

Identifiers

PMID28295259
PMCPMC5582540
OpenAlexW2596603613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.